Enanta Pharmaceuticals, Inc. (ENTA)Â
NASDAQ$6.65
Market Cap
$141.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
219 of 924
Rank in Industry
128 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ENTA Insider Trading Activity
ENTA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $256,050 | 1 | 9 |
Sells | $407,330 | 10 | 91 |
Related Transactions
| Luly Jay R. | President and CEO | 1 | $256,050 | 1 | $41,445 | $214,605 |
| Luu Brendan | Chief Business Officer | 0 | $0 | 1 | $18,401 | $-18,401 |
| MELLETT PAUL J | Chief Fin. & Admin Officer | 0 | $0 | 1 | $20,883 | $-20,883 |
| Or Yat Sun | Chief Scientific Officer | 0 | $0 | 1 | $20,883 | $-20,883 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 0 | $0 | 2 | $107,991 | $-107,991 |
| Rottinghaus Scott T. | Chief Medical Officer | 0 | $0 | 4 | $197,727 | $-197,727 |
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Activity of Enanta Pharmaceuticals, Inc.
Over the last 12 months, insiders at Enanta Pharmaceuticals, Inc. have bought $256,050 and sold $407,330 worth of Enanta Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Enanta Pharmaceuticals, Inc. have bought $256,050 and sold $2.67M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Luly Jay R. (President and CEO) — $256,050.
The last purchase of 45,000 shares for transaction amount of $256,050 was made by Luly Jay R. (President and CEO) on 2025‑02‑12.
List of Insider Buy and Sell Transactions, Enanta Pharmaceuticals, Inc.
| 2025-02-12 | Luly Jay R. | President and CEO | 45,000 0.2147% | $5.69 | $256,050 | +28.90% | ||
| 2024-12-06 | Sale | Luly Jay R. | President and CEO | 5,142 0.0244% | $8.06 | $41,445 | -25.00% | |
| 2024-12-06 | Sale | Or Yat Sun | Chief Scientific Officer | 2,591 0.0123% | $8.06 | $20,883 | -25.00% | |
| 2024-12-06 | Sale | MELLETT PAUL J | Chief Fin. & Admin Officer | 2,591 0.0123% | $8.06 | $20,883 | -25.00% | |
| 2024-12-06 | Sale | Luu Brendan | Chief Business Officer | 2,283 0.0108% | $8.06 | $18,401 | -25.00% | |
| 2024-12-06 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 2,283 0.0108% | $8.06 | $18,401 | -25.00% | |
| 2024-12-06 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 866 0.0041% | $8.06 | $6,980 | -25.00% | |
| 2024-07-15 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 5,375 0.0355% | $17.08 | $91,805 | -36.94% | |
| 2024-07-12 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 2,271 0.0132% | $15.04 | $34,156 | -34.69% | |
| 2024-07-11 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 4,299 0.0251% | $15.07 | $64,786 | -30.15% | |
| 2024-06-17 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 7,266 0.0315% | $12.33 | $89,590 | -9.28% | |
| 2023-12-13 | Sale | Vance Terry | director | 15,295 0.0684% | $9.12 | $139,490 | +27.84% | |
| 2023-12-05 | Sale | Luly Jay R. | President and CEO | 7,230 0.0351% | $9.63 | $69,625 | +30.94% | |
| 2023-12-05 | Sale | Or Yat Sun | Sr. VP, R&D & CSO | 2,412 0.0117% | $9.63 | $23,228 | +30.94% | |
| 2023-12-05 | Sale | MELLETT PAUL J | Sr. VP, Finance & Admin. & CFO | 2,412 0.0117% | $9.63 | $23,228 | +30.94% | |
| 2023-12-05 | Sale | Gardiner Nathaniel S. | Sr. VP & General Counsel | 2,412 0.0117% | $9.63 | $23,228 | +30.94% | |
| 2023-12-05 | Sale | Kieffer Tara Lynn | Sr. VP, New Prod. Strat. & Dev | 2,125 0.0103% | $9.63 | $20,464 | +30.94% | |
| 2023-12-05 | Sale | Luu Brendan | Sr. VP, Business Dev. | 2,125 0.0103% | $9.63 | $20,464 | +30.94% | |
| 2023-12-05 | Sale | Rottinghaus Scott T. | Sr. VP & CMO | 534 0.0026% | $9.63 | $5,142 | +30.94% | |
| 2023-03-15 | Sale | Or Yat Sun | Sr. VP & CSO | 13,925 0.0661% | $44.45 | $618,960 | -67.45% |
Total: 128
*Gray background shows transactions not older than one year
Insider Historical Profitability
11.84%
| Luly Jay R. | President and CEO | 846638 3.9688% | $5.63M | 1 | 18 | |
| Or Yat Sun | Chief Scientific Officer | 369109 1.7303% | $2.45M | 0 | 19 | |
| MELLETT PAUL J | Chief Fin. & Admin Officer | 91710 0.4299% | $609,871.50 | 0 | 21 | |
| Luu Brendan | Chief Business Officer | 36047 0.169% | $239,712.55 | 0 | 2 | |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 29305 0.1374% | $194,878.25 | 0 | 3 | |
| Rottinghaus Scott T. | Chief Medical Officer | 17918 0.084% | $119,154.70 | 0 | 5 | |
| Goldberg Marc E. | director | 547606 2.567% | $3.64M | 0 | 3 | |
| SCHUHSLER HELMUT | 380487 1.7836% | $2.53M | 1 | 3 | +19.31% | |
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | 10 percent owner | 276999 1.2985% | $1.84M | 1 | 7 | +19.31% |
| Gardiner Nathaniel S. | Sr. VP & General Counsel | 68154 0.3195% | $453,224.10 | 3 | 2 | +9.2% |
| Adda Nathalie | Sr. VP & Chief Medical Officer | 47191 0.2212% | $313,820.15 | 0 | 14 | |
| AFTING ERNST-GUENTER | director | 17287 0.081% | $114,958.55 | 0 | 1 | |
| SAINTS CAPITAL GRANITE, L.P. | 10 percent owner | 16904 0.0792% | $112,411.60 | 1 | 8 | +19.31% |
| Ocain Tim | Senior Vice President | 6127 0.0287% | $40,744.55 | 0 | 1 | |
| Vance Terry | director | 5800 0.0272% | $38,570.00 | 2 | 1 | +8.96% |
| CARTER BRUCE L A | 3324 0.0156% | $22,104.60 | 0 | 4 | ||
| Verdine Gregory L. | director | 3324 0.0156% | $22,104.60 | 1 | 0 | +19.31% |
| Buckley Stephen Jr. | director | 2000 0.0094% | $13,300.00 | 3 | 0 | +6.42% |
| Golumbeski George | director | 0 0% | $0 | 0 | 3 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$30,470,407 | 140 | 20.39% | $134.78M | |
$860,541,348 | 82 | -5.10% | $132.49M | |
$2,924,567 | 72 | -4.87% | $157.74M | |
$909,129 | 37 | 42.19% | $127.55M | |
$35,190,048 | 32 | 37.32% | $150.49M | |
$64,487,106 | 32 | -22.92% | $140.02M | |
$40,617,659 | 23 | 2.15% | $139.33M | |
$6,915,275 | 21 | -32.61% | $158.47M | |
$2,484,989 | 17 | -17.86% | $156.9M | |
$91,870,774 | 13 | 3.64% | $151.62M | |
Enanta Pharmaceuticals, Inc. (ENTA) | $10,143,329 | 12 | 11.84% | $141.86M |
$3,871,238 | 10 | -30.38% | $130.76M | |
$135,589,307 | 10 | 32.46% | $126.14M | |
$45,000,000 | 6 | -31.22% | $129.73M | |
$556,839 | 5 | 13.42% | $144.11M | |
$63,981 | 5 | -11.55% | $156.07M | |
$4,256,958 | 4 | 22.95% | $129.54M | |
$32,289,200 | 3 | -5.46% | $143.67M | |
$879,499 | 1 | 28.50% | $154.55M |
ENTA Institutional Investors: Active Positions
| Increased Positions | 59 | +45.74% | 3M | +15.54% |
| Decreased Positions | 55 | -42.64% | 5M | -21.7% |
| New Positions | 24 | New | 2M | New |
| Sold Out Positions | 25 | Sold Out | 2M | Sold Out |
| Total Postitions | 133 | +3.1% | 20M | -6.15% |
ENTA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Krensavage Asset Management, Llc | $16,473.00 | 10.08% | 2.12M | +619,316 | +41.34% | 2024-12-31 |
| Farallon Capital Management Llc | $16,402.00 | 10.04% | 2.11M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $15,868.00 | 9.71% | 2.04M | +139,319 | +7.33% | 2024-12-31 |
| Vanguard Group Inc | $15,437.00 | 9.45% | 1.98M | +2,298 | +0.12% | 2024-12-31 |
| Morgan Stanley | $9,504.00 | 5.82% | 1.22M | +118,743 | +10.77% | 2024-12-31 |
| Ra Capital Management, L.P. | $8,076.00 | 4.94% | 1.04M | +1M | New | 2024-12-31 |
| Marshall Wace, Llp | $7,236.00 | 4.43% | 930,087 | +79,197 | +9.31% | 2024-12-31 |
| Millennium Management Llc | $6,979.00 | 4.27% | 896,987 | +165,692 | +22.66% | 2024-12-31 |
| Acadian Asset Management Llc | $6,609.00 | 4.05% | 849,424 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $3,874.00 | 2.37% | 498,000 | -26,900 | -5.13% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.